Abivax S.A. ABVX

Key data

The business

Abivax is a French clinical-stage company based in Paris and the US with essentially one product: obefazimod, a once-daily oral pill for ulcerative colitis. Ulcerative colitis is a chronic disease where the lining of the large intestine stays inflamed and ulcerated, causing bleeding, urgency and pain, and patients cycle through drugs looking for lasting remission. Obefazimod is a small molecule that enhances a single micro-RNA called miR-124, a natural brake on inflammation (Vautrin et al., Scientific Reports 2018, DOI 10.1038/s41598-018-37813-y). That mechanism is unlike the JAK inhibitors, S1P modulators and antibody injections that dominate the market today, and it is a pill, not a shot. The company earns no product revenue: every euro spent is research, and every euro of cash has come from selling stock and, until this year, royalty certificates. The moat, if the drug reaches the market, is a differentiated mechanism protected by patents and a remission profile competitors cannot easily copy. The whole company rides on one molecule.

The numbers

Read the losses, not revenue, because there is none. The picture is a widening burn punctuated by non-cash charges.

The €153 million third-quarter loss is not the operating business. Operating loss that quarter was €80.7 million, and the rest was a non-cash charge tied to the royalty certificates the company later bought back in May 2026. Strip the noise and the real cash burn runs near €45 million to €55 million a quarter and is rising as pre-launch spending starts.

The balance sheet, not the income statement, decides the next year. Cash, equivalents and short-term investments stood at €491.6 million on March 31, 2026, which the company says funds operations into the fourth quarter of 2027, about twelve months past its planned application to the FDA. That is enough to file and get an answer, not enough to launch, so a large raise is coming. Shares outstanding have gone from roughly 15 million in 2021 to about 73 million now, so each de-risking milestone was paid for by existing owners. Analysts model almost no revenue until launch, then a fast ramp: about $506 million in 2028 and $1.25 billion in 2029, the first year the company might turn a profit. What this memo believes that the price may not: the maintenance remission numbers, roughly 40 points above placebo, are strong enough that peak sales could clear the crowded-market discount baked into today's estimates, and the print that settles it is the FDA's acceptance of the filing and the first two quarters of prescriptions.

Management

There are no insider buys or sells on file in the last twelve months, so read management by what it did with the balance sheet. The record is serial dilution in service of one asset: the share count has roughly quintupled in five years, and in May 2026 the company sold another $45 million of American shares. That same month it repurchased and cancelled its royalty certificates, removing a claim on future drug sales and cleaning up the capital structure ahead of a launch. The real choice was concentration. Rather than build a pipeline, management poured everything into obefazimod and the Phase 3 program, and in June 2026 the positive 44-week maintenance data vindicated it. Pay and proxy detail are not disclosed in this run. The next capital decision, how much to raise for launch and at what price, will matter more to current owners than any trial result from here.

How it fails or surprises you

Regulatory rejection or a narrow label. The entire value rests on FDA approval of a single drug. A complete response letter, a safety signal surfacing in the larger maintenance database, or a label restricted to the sickest patients would gut the commercial case. The first print is FDA acceptance of the planned application and any advisory-committee scheduling that follows.

Financing at a bad price. Cash runs into Q4 2027 and covers filing, not launch. Abivax must raise likely several hundred million dollars into a stock already down from $148.83 to $114.79. If the raise lands after a market wobble or a soft data point, the dilution to current owners could be severe. Watch the cash line each half-year and any shelf takedown.

Best-in-class oral takes real share (right tail). Placebo-adjusted maintenance remission near 40 points, from a pill without JAK-class safety warnings, is a genuinely strong profile. If real-world use confirms it, obefazimod could win first-line oral share and clear the $1.25 billion 2029 estimate, with Crohn's disease as a second, unpriced market. The first tell is the Phase 2b Crohn's readout and launch-quarter scripts.

Closing thoughts

This is the kind of situation a specific event resolves, not a slow grind. The pivotal science question, does the drug work, was answered yes in June. What remains is a sequence of yes-or-no prints: the FDA accepts the filing, the drug is approved on a broad label, and the first prescriptions confirm doctors will actually reach for it. A clean run of those converts today's $8.4 billion into a plausibly cheap number against a multi-billion-dollar drug. An ambiguous print, a delayed filing, a narrow label, a slow launch, leaves a single-product company burning cash and needing money, and any of those is the moment to reassess rather than average down. The left tail is real and permanent, since one regulatory or safety surprise ends it. The right tail is a best-in-class oral in a large market, worth multiples of the current price if it lands.

The bet is still that obefazimod becomes a standard pill for ulcerative colitis and wins patients from the injections and harsher orals already on the market. What breaks it is running out of money before that happens, or a regulator saying no. The one pair of numbers that tells you first is the cash balance against the burn, €491.6 million falling toward a Q4 2027 wall, set against the timing of FDA acceptance. If the filing is accepted and a launch-ready raise is done from strength, the bet is intact. If the cash line drops without a financing on good terms, it is not.